Castle Biosciences Study Shows TissueCypher Test Altered Management in 90% of NDBE Patients

Castle Biosciences Inc. (CSTL) announced on Sept. 28, 2026, the publication of a study showing its TissueCypher Barrett's Esophagus Test guided risk-aligned management changes in 90% of patients with non-dysplastic Barrett's esophagus (NDBE). The test is designed to predict progression risk in NDBE patients, a population that typically undergoes periodic surveillance endoscopy. The study results suggest the assay may influence clinical decision-making for this patient group. Additional study details, including sample size and publication venue, were not disclosed in the announcement. Castle Biosciences, based in Friendswood, Texas, develops molecular diagnostics for dermatologic and gastroenterologic conditions.